Streetbeat News

Regulatory

CNGL

Trading for CNGL was halted at 4:45:36 p.m. ET due to pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:45 pm

CNGLU

Trading for CNGLU was halted at 4:45:36 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:45 pm

BAC

C

GS

KRE

USB

WFC

XLF

JPMorgan analyst Vivek Juneja reacted to the Federal Reserve’s annual stress test results for U.S. banks, highlighting a substantial increase in stress capital buffers (SCB) for large-cap banks. This increase may delay or reduce long-term capital return plans. Citigroup fared well, while Goldman Sachs and Wells Fargo faced significant SCB increases. U.S. Bancorp was downgraded from Overweight to Neutral. Bank ETFs like XLF fell, while regional banks outperformed.

Portfolio Pulse from Hayden Buckfire

June 27, 2024 | 8:38 pm

FFIE

Faraday Future Intelligent Electric (FFIE) has announced that Nasdaq has approved the continued listing of its stock, subject to certain compliance deadlines.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:32 pm

NUTX

Nutex Health Inc. (NASDAQ:NUTX) announced a 1-for-10 reverse stock split effective July 3, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:30 pm

IBIT

Cryptocurrency markets are rallying ahead of the Trump-Biden U.S. Presidential election debate, with a Solana spot ETF application by VanEck as a key catalyst. Bitcoin, Ethereum, and Dogecoin are among the gainers. Notable developments include BlackRock's purchase of Bitcoin for its Global Allocation Fund and Coinbase suing the SEC and FDIC. Analysts caution about potential liquidations if Bitcoin drops to $60,700.

Portfolio Pulse from Khyathi Dalal

June 27, 2024 | 8:21 pm

DVAX

Dynavax has initiated a Phase 1/2 study for its novel shingles vaccine, Z-1018, to evaluate its safety, tolerability, and immunogenicity.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:10 pm

ACST

Acasti Pharma has reached 50% enrollment in its pivotal Phase 3 STRIVE-ON safety trial. This milestone is significant for the company's development of its lead drug candidate, GTX-104, aimed at treating subarachnoid hemorrhage. The trial's progress is a positive indicator for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:06 pm

QUBT

Quantum Computing Inc. (QUBT) has received a notice from Nasdaq indicating that it has failed to meet the standard for continued listing. This could have significant implications for the company's stock price and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:01 pm

ERJ

The FAA reported that an Embraer business jet went off the runway at Newark Airport, causing a temporary runway closure.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 7:46 pm